 |
|
Butterbur Ze339 for the Treatment of Intermittent Allergic Rhinitis
Dose-Dependent Efficacy in a Prospective, Randomized, Double-blind, Placebo-Controlled Study
Andreas Schapowal, MD, PhD; for the Petasites Study Group
Arch Otolaryngol Head Neck Surg. 2004;130:1381-1386.
Objectives To investigate whether the efficacy and safety of Butterbur extract Ze339 are related to dosage when administered to patients with intermittent allergic rhinitis.
Design Prospective, randomized, double-blind, placebo-controlled, parallel-group comparison.
Setting Multicenter, including 6 outpatient general medicine and allergy clinics.
Patients One hundred eighty-six patients were randomized (Butterbur Ze339 high dose, 60; low dose, 65; and placebo, 61 patients). Established diagnostic criteria for intermittent allergic rhinitis were confirmed by skin allergy tests in all patients.
Interventions High-dose group, 1 tablet 3 times daily; low-dose group, 1 tablet twice daily; or matching placebo. All groups were treated for 2 consecutive weeks.
Main Outcome Measures The main efficacy variable was change in symptoms from baseline to end point during the daytime. The secondary efficacy variables were Clinical Global Impression score, change in symptoms from baseline to treatment day 7, and responder rates. Statistical analysis was prospective, on an intention-to-treat basis.
Results Improvement in the main efficacy variable was significantly superior in the Butterbur Ze339 groups, relative to placebo, and a significant dose relationship was observed between the 2 Butterbur doses. The clinicians’ assessment of efficacy and the overall responder rates were significantly superior for the active groups compared with placebo. The incidence and type of adverse events were indistinguishable across the herbal treatment and placebo groups.
Conclusions Butterbur Ze339 is an effective treatment for intermittent allergic rhinitis symptoms and is well tolerated. The effects of this herbal medicine are clear to patients and physicians in a double-blind evaluation against placebo.
Author Affiliation: Allergy Clinic, Landquart, Switzerland.
Group Information: The Petasites Study Group coordinator is Ewald Schrader, Pohlheim, Germany. Investigators include the author and Hartmut Wältner, Albstadt, Germany; Rüdiger Schellenberg, Hüttenberg, Germany; Alexander Massing, Offenbach, Germany; Manfred Kortüm, Schrecksbach, Germany; and Wolf Kaiser, Erfurt, Germany.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Addressing the Long-term Safety Aspects of Butterbur Therapy: A Call for Immediate Action
Lee
Arch Otolaryngol Head Neck Surg 2005;131:539-540.
FULL TEXT
|
